C yclooxygenase (COX)
1 is the initial enzyme in the conversion of arachidonic acid to metabolites including prostacyclin (PGI 2 ), TXA 2 , and PGE 2 , which have a variety of biological actions involved in the maintenance of vascular homeostasis. PGI 2 is released mainly by endothelial cells, 2 acts on IP receptors linked to the activation of adenylyl cyclase, 3 inhibits platelet aggregation, causes vasodilatation, 2 reduces cholesterol accumulation, 4 and inhibits vascular smooth muscle cell (SMC) proliferation. 5 TXA 2 is released mainly by platelets, acts on TP receptors linked to the inositol phosphate pathway, causes vasoconstriction, and stimulates platelet aggregation.
3 PGE 2 is released by leukocytes as well as endothelial cells and acts on a variety of EP receptors linked to different transduction pathways; therefore, it can produce different vascular responses, depending on the distribution of particular EP receptor subtypes. 3 In healthy vessels, endothelial cells are enriched with COX activity, 2 whereas the underlying smooth muscle releases considerably lower amounts of prostanoids. 6 Under such conditions, the release of COX metabolites by endothelium is regulated by a constitutively expressed isoform of COX (COX-1) 7 . Thus, when the endothelium is damaged, COX-1 activity and the release of PGI 2 are reduced, thereby rendering the vessel susceptible to vasospasm, thrombosis, and atherosclerosis.
Recently, a cytokine-or mitogen-induced isoform of COX was identified (COX-2) in chick 8 and murine 9 fibroblasts and was demonstrated consequently in a variety of human cell types including endothelial cells, 10 monocytes, 11 airway epithelial cells, 12 and airway smooth muscle 13 in vitro. In addition, COX-2 also has been demonstrated at the site of inflammation in vivo. 14, 15 Agents that induce COX-2 include interleukin-1␤ (IL-1␤), tumor necrosis factor-␣ (TNF-␣), bacterial lipopolysaccharide (LPS), growth factors, and phorbol esters. 16 Furthermore, COX-2 is induced in rat vascular SMC treated with platelet-derived growth factor or transforming growth factor-␤ in vitro and in rat vessels after physical trauma in vivo. 17 We recently have shown that COX-2 is induced in intact segments of human saphenous vein (SV) and internal mammary artery (IMA) in organ culture. 18 However, in these studies, the cellular origin of COX-2 was not determined. Considering that vascular smooth muscle is a major component of the vascular tree, it is important to establish the role of COX-2 in prostanoid release by these cells under physiological and pathophysiological conditions. Moreover, we have found that human veins express significantly more COX-2 activity after induction than human arteries. 18 Whether this differential expression is due to fundamental differences in the ability of venous and arterial SMC to express COX-2 is not clear. Thus, in the current report, we have compared the ability of human arterial and venous SMC in culture to release COX products and express COX-2 protein in response to a variety of inflammatory stimuli. Furthermore, we have investigated any possible feedback mechanisms that prostanoids may have on COX-2 induction in the 2 cell types.
Methods

Materials
Human recombinant IL-1␤ and TNF-␣ were from BoehringerMannheim; IFN-␥ was from R&D Systems; tritiated prostanoids were from Amersham; all cell culture media and supplements were supplied by Gibco BRL; L-745,337 [5-methanesulfonamido-6-(2,4-difluorothiophenyl)-1-indanone] and selective COX-1 and COX-2 antibodies were a gift from Merck Frosst; all other reagents and antibodies were from Sigma Chemical Co.
Human Vessels
Segments of undistended SV (nϭ5) and IMA (nϭ6) were obtained from patients undergoing coronary artery bypass surgery; 4 of these IMAs and SVs were obtained from the same patients. Ethical permission was obtained from the Ethical Committee of the Royal Brompton National Heart and Lung Hospital. All vessels were used regardless of preoperative drug therapy or patient history.
Vessel Collection and Cell Culture
All vessels were placed immediately into sterile pots containing sterile PBS (Pen-Strep) supplemented with penicillin (100 IU/mL) and streptomycin (0.1 mg/mL; Pen-Strep) and prepared immediately or stored at 5°C for no more than 2 hours before preparation. Vascular SMCs were grown by explant outgrowth method, in DMEM containing 1 mmol/L sodium pyruvate and phenol red, supplemented with Pen-Strep, 2 mmol/L glutamine DMEM, and 20% FBS (37°C, 5% CO 2 , 95% air). SMCs were identified by characteristic morphological "hill-and-valley" growth pattern and by smooth muscle ␣-actin immunostaining.
COX Activity in Human Arterial and Venous Smooth Muscle
COX activity, supported by either endogenous or exogenous sources of arachidonic acid, was measured in cells (only passages 2 to 6 were used) cultured on 96-well tissue culture plates. COX activity utilizing endogenous stores of arachidonic acid was measured by the release of prostanoids in the supernatant of cells treated with different combinations of drugs for 6-, 12-, 24-, or 48-hour time periods. The prostanoid release in these experiments relies on the activity of both phospholipases (eg, A 2 ) to liberate membrane-bound arachidonic acid and COX. In experiments designed to asses COX activity directly (ie, without the contribution of phospholipases), cells were treated with the relevant cytokines/drugs for the designated times (as described above), and the culture medium was replaced for 15 minutes with fresh medium containing arachidonic acid (30 mol/L). The agents used to study COX induction were IL-1␤ (10 ng/mL), TNF-␣ (10 ng/mL), LPS (Escherichia coli; serotype 0111:B4; 10 g/mL), or IFN-␥ (1000 U/mL; 24 and 48 hours only), or a "cytokines mix" consisting of IL-1␤, TNF-␣, LPS, and IFN-␥. In separate experiments, SMCs were treated with the COX-1/COX-2 inhibitor indomethacin 7, 19 or its COX-2-selective derivative L-745,337 20 (10 pmol/L to 100 mol/L for both) 30 minutes before addition of the cytokine mixture for an additional 24 hours. The medium was then removed, and prostanoids were measured by radioimmunoassay. Stocks of indomethacin or L-745,337 (100 mmol/L) were dissolved in dimethyl sulfoxide and diluted in DMEM. All nonsterile aqueous solutions were filtered (0.2 m) before addition to the cells.
Western Blot Analysis for COX-1 and COX-2
SV or IMA SMCs were seeded on 6-well plates and left untreated or treated with the mixture of cytokines for 24 hours. In some experiments, L-745,337 (10 mol/L) was also added to the cells. The medium was then removed, cells were washed with PBS, and proteins were extracted with a Tris buffer (50 mmol/L; pH 7.4) containing 10 mmol/L EDTA, 1% vol/vol Triton-X 100, and 1 mmol/L PMSF. Extracts were boiled at a 1:1 ratio with Tris (50 mmol/L; pH 6.8; 4% wt/vol SDS; 10% vol/vol glycerol; 4% vol/vol 2-mercaptoethanol; 2 mg/mL bromophenol blue). Samples of equal protein were loaded onto 7.5% Tris-glycine SDS gels and were separated by electrophoresis. 21 After transfer to nitrocellulose, the blots were primed with either a selective anti-human COX-1 or a specific anti-human COX-2 antibody 20 (Merk Frosst) raised in rabbit. The blots were then incubated with anti-rabbit IgG (raised in donkey), conjugated to horseradish peroxidase, and developed by ECL (Amersham International Ltd). Rainbow markers (14 000 to 200 000 kDa; Amersham International Ltd) were used for molecular weight determinations.
Prostanoid Determination
PGE 2 was used as the main index of COX activity because it was the predominant PG released. 6-Keto PGF 1␣ (the hydrolysis product of PGI 2 ), TXB 2 (the hydrolysis product of TXA 2 ), and PGE 2 were measured by radioimmunoassay using commercial antibodies and tritiated prostanoids, as previously described. 7 Antibodies to 6-keto PGF 1␣ or TXB 2 did not cross-react with disparate prostanoids. However, PGE 2 displayed Ϸ15% cross-reactivity with the antibody to 6-keto PGF 1␣ . 22 Statistics were calculated from Prism 2.01 (Graphpad Software) using the appropriate recommended test (see appropriate figure legends).
Results
Effect of IL-1␤, TNF-␣, IFN-␥, or LPS on COX Activity in Cultures of Human SV and IMA SMC
Unstimulated venous and arterial SMC released 12Ϯ3 and 13Ϯ2 ng/mL PGE 2 , respectively, over 48 hours. Either IL-1␤ (10 ng/mL; Figure 1A ) or TNF-␣ (10 ng/mL; Figure 2A ) caused a time-dependent release of PGE 2 from endogenous stores of arachidonic acid by both venous and arterial SMC. Similarly, COX activity, supported by exogenous arachidonic acid, was increased in both venous and arterial cells by IL-1␤ ( Figure 1B ) or TNF-␣ ( Figure 2B ). LPS ( Figure 3 ) significantly increased the release of PGE 2 and COX activity in venous but not arterial cells. Venous cells released consistently more PGE 2 than arterial cells when stimulated with IL-1␤ (Figure 1 ). In contrast, venous and arterial cells released similar amounts of PGE 2 (from either endogenous or exogenous stores of arachidonic acid) after stimulation with either TNF-␣ or LPS (Figures 2 and 3) . INF-␥ (1000 U/mL) had no significant effect on COX activity in either cell type (data not shown). Stimulants had the following rank order of efficiency as inducers of COX activity: IL-1␤ϾTNF-␣ϾLPSϾϾINF-␥ (Figures 1, 2, and 3) . 
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Effect of a Combination of IL-1␤, TNF-␣, LPS, and INF-␥ on COX Activity in Human Arterial and Venous SMC
A mixture of IL-1␤ (10 ng/mL), TNF-␣ (10 ng/mL), IFN-␥ (1000 U/mL), and LPS (10 g/mL) produced an "additive" effect on COX activity from arterial SMC but acted in synergy in venous SMC (Figure 4) . Indeed, the maximum release of PGE 2 in response to the "cytokine mixture" by venous SMC (Figure 4 ) was Ϸ5-fold greater than the sum of the release by individual cytokines (Figures 1, 2 , and 3). In separate experiments (nϭ9), cells treated with the cytokine mixture released mainly PGE 2 (for arterial cells, 77Ϯ5 ng/mL; for venous cells, 846Ϯ107) but also increased levels of 6-keto-PGF 1␣ (for arterial cells, 19Ϯ1 ng/mL; for venous cells, 84Ϯ4 ng/mL), but not levels of TXB 2 (Ͻ0.1 ng/mL for arterial or venous cells) after 48 hours.
Induction of COX Protein in SV and IMA
COX-1 protein could not be detected in extracts of either arterial or venous cells cultured in the presence or absence of cytokines (data not shown). Similarly, under control culture conditions, no protein for COX-2 was detected in extracts of arterial or venous SMC ( Figure 5 ). However, when either arterial or venous SMCs were stimulated for 24 hours with the mixture of cytokines, a band at Ϸ70 kDa was recognized by the specific COX-2 antibody ( Figure 5 ). Furthermore, a second band of Ϸ60 kDa 20 was induced along with the COX-2 protein after cytokine treatment. A protein of Ϸ40 kDa was also recognized by the COX-2 antibody, although the expression of this protein did not change with cytokines (data not shown). In keeping with the differences in COX activity, the amount of COX-2 protein induced by the cytokine mixture was Ϸ3-fold higher in venous SMC cultures than in arterial SMC cultures (0. Figure 7 ). L-745,337 had no effect on the amount of COX-2 protein in unstimulated cells (data not shown). In contrast to its effects on COX-2 expression, L-745,337 inhibited the level of the coinduced 60-kDa protein by 89Ϯ5% in venous SMC and by 72Ϯ13% in arterial SMC (nϭ3; Figures 6 and 7) . In separate experiments, PGE 2 (1 mol/L) but not cicaprost (1 mol/L) inhibited the expression of COX-2 in cytokine-treated arterial SMCs (Figure 8 
Effects of the COX-2-Selective Inhibitor L-745,337 and the COX-1/COX-2 Inhibitor Indomethacin on PGE 2 Release by Arterial and Venous SMC
The inhibitor L-745,337 is approximately equipotent with indomethacin as an inhibitor of purified COX-2 and Ͼ500 times less potent than indomethacin as an inhibitor of COX-1. 20 Thus, where L-745,337 is equipotent with indomethacin, COX-2 is likely to predominate. In our experiments, both L-745,337 and indomethacin caused concentration-dependent reductions in PGE 2 
Discussion
Arachidonic acid metabolites formed by the COX pathway have potent actions on vascular smooth muscle contractility, 2,3,6 growth, 3, 5, 23 and cholesterol uptake. 4 Within vessels, the majority of COX present is in the constitutive form, COX-1, which is expressed mainly in the endothelial layer, with much lower levels being present in the underlying smooth muscle. 6 However, data from animal models have suggested that when the endothelium is compromised or vessels are damaged, the inducible isoform, COX-2, can be expressed in vascular smooth muscle. 17 Here, we show that COX activity can be increased greatly in human vascular SMC by different cytokines and that, under optimum conditions, venous SMCs have the capacity to release much higher levels of prostanoids than arterial SMC.
Both venous and arterial SMCs released low levels of COX metabolites when cultured in the absence of cytokines. This observation is consistent with the notion that SMCs do not normally express COX enzymes. However, after treatment with either TNF-␣, LPS, IL-1␤, or "cytokine mix," both arterial and venous SMCs release increased amounts of COX metabolites. Of the metabolites measured, PGE 2 was released preferentially followed by PGI 2 (measured as its breakdown product, 6-keto-PGF 1␣ ), with very low levels of TXB 2 . This pattern of release is consistent with our 18, 24 and other 25 previous findings, confirming the presence of PGI 2 synthetase in arterial and venous SMC [25] [26] [27] and that only low levels of TXA 2 synthetase are present. The large amounts of PGE 2 released may be due to saturation of the PGI 2 synthetase pathway and PGH 2 being converted nonenzymatically 28 to PGE 2 , although a specific link between COX-2 and increasing PGE 2 isomerase activity has been suggested recently. 29 Venous and arterial cells released similar amounts of PGE 2 under "basal conditions" or when stimulated to release greater amounts with TNF-␣. However, when cells were stimulated with IL-1␤ or the mixture of cytokines, venous cells released greater amounts of PGE 2 than did arterial cells. Similarly, cytokine-stimulated venous cells expressed significantly more COX-2 protein than did arterial cells. In contrast to bovine aortic endothelium 30 or rat aortic vascular SMCs 31 in culture, human venous and arterial vascular SMCs were relatively insensitive to LPS as an inducer of COX-2. As freshly isolated human SV or IMA release PGs readily to LPS, 32 this insensitivity may be the result of long-term culture of human SMC.
The nonsteroidal anti-inflammatory drug indomethacin is a potent nonselective inhibitor of COX-1 and COX-2 12, 19 ; recently, a COX-2-selective derivative, L-745,337, has been described. 20 L-745,337 is equipotent with indomethacin as an inhibitor of COX-2 but Ͼ500 times less potent as an inhibitor of COX-1. We found indomethacin and L-745,337 to be approximately equipotent inhibitors of the cytokine-induced release of PGE 2 by both venous and arterial cells. This observation is again consistent with COX-2 being the active isoform present in our SMC cultures. Interestingly, both indomethacin and L-745,337 were more potent inhibitors of COX in arterial cells than in venous cells. Because arterial cells express less COX-2 than venous cells, nonsteroidal anti-inflammatory drugs may have easier access to protein and thereby be more potent. Indeed, preliminary data obtained by us, using pure COX-2 protein, show that the relative potency of indomethacin increases with lower amounts of enzyme (J.A.M., unpublished data, 1998).
Why, then, do venous cells express more COX-2 protein and activity than equally treated arterial cells? One possible explanation could be that products formed by the COX pathway limit the induction of COX-2 in arterial cells but not in venous cells. In cytokine-treated cells, when COX-2 activity was blocked with the selective inhibitor L-745,337, the expression of COX-2 protein in arterial but not in venous cells was increased. Moreover, COX-2 expression in arterial cells was strongly inhibited by exogenously applied PGE 2 . This observation is consistent with a recently published study 38 ; using porcine aortic SMC, the authors showed that exogenous PGE 2 suppresses the induction of COX-2 stimulated by either U46619 (a thromboxane mimetic) or basic fibroblast growth factor. Thus, our data suggest that a "feedback" system exists to limit COX-2 induction in some SMC. Interestingly, the IP receptor agonist, cicaprost, did not affect the expression of COX-2 in either cell type. These observations suggest that COX-2 expression is modulated by EP receptor activation in these arterial cells. Indeed, the differences observed between arterial and venous cells may reflect variations in the prostanoid receptor population expressed on the 2 types of smooth muscle. 33, 34 Similar to the predicted 70-kDa COX-2 protein, both arterial and venous SMC expressed a protein of Ϸ60 kDa. Similar observations have been made in other cells expressing COX-2 and in purified protein, 20 where the 60-kDa protein was thought to be a breakdown product of COX-2. We found that the 60-kDa protein was inhibited by L-745,337 in both arterial and venous cells but that COX-2 protein was increased only in the arterial cells. Thus, the 70-kDa COX-2 and the unidentified 60-kDa protein appear to be regulated independently. However, the inhibitory effect of L-745,337 on the expression of the 60-kDa protein was reversed by exogenous PGE 2 ( Figure 8 ). This observation suggests that the 60-kDa protein, like COX-2 expression, is also regulated by PGE 2 release.
The venous and arterial cells used in our study were derived from SV and IMA, 2 commonly used bypass conduits. The artery is the vessel of first choice because it has a lower incidence of reocclusion than the vein. However, with the common need for multiple grafts, and because the artery is not always suitable for grafting, 35 SV is still commonly used. The primary reason for graft failure is reocclusion due to atherosclerosis, a process that involves smooth muscle proliferation, inflammatory cell invasion, and lipid accumulation. 36 COX-2 products released by cells in this study were mainly PGE 2 and PGI 2 , which are thought to be antilipidemic via both cAMPdependent activation of cytosolic neutral cholesteryl ester hydrolase and independent activities on other cholesteryl ester cycle enzymes. 4 Thus, the induction of COX-2 in IMA and SV SMC may act to reduce cholesterol uptake and metabolism. Furthermore, the release of PGs after COX-2 induction could also inhibit the activity and adhesion of platelets 2 and may play a feedback role on the release of cytokines such as IL-1␤, TNF, and CSF-1 (macrophage CSF). 4 Thus, induction of COX-2 in vascular SMC may represent a compensatory mechanism that ensures the release of PGI 2 and PGE 2 when endothelium is compromised. However, COX-2 induction also may have detrimental effects on vascular function. For example, the peroxidase activity of COX can oxidize lipids, 37 producing potent atherogenic stimuli. Furthermore, COX activity in human SV results in vasoconstriction, whereas COX activity in human IMA results in vasodilation. 33 Thus, the consequences of COX-2 expression in vascular smooth muscle may differ, depending on the type and origin of the vessel.
We have demonstrated recently, using an organ culture technique, that COX-2 is induced in segments of SV to a greater level than in IMA. 18 Here, we have extended these studies and identified vascular smooth muscle as an important site of COX-2 induction. Moreover, we have established, similarly to observations in intact tissue, 18 that venous cells (even at passage 6) are capable of expressing much greater amounts of COX-2 activity than similarly cultured arterial cells. Furthermore, in arterial cells, but not in venous cells, COX-2 products negatively regulate the expression of COX-2, thereby explaining why arterial cells express less COX-2. These observations add to our current understanding of COX-2 regulation 1, 16 and establish human vascular smooth muscle as an important site for COX-2 expression. As COX-2 in human vascular SMC is regulated by cytokines found in several vascular diseases, we hypothesize that COX-2 will be expressed rapidly as a response to vascular injury and is likely therefore to play a role in modulating and controlling subsequent vascular pathologies.
